2 results
Approved WMOCompleted
To demonstrate the additive IOP lowering effect of SIMBRINZA (dosed BID) when added to DUOTRAV solution in subjects with open-angle glaucoma or ocular hypertension.
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…